Blood-filter treatment during heart transplant surgery
Part of Heart & circulation clinical trials.
This study tests whether a blood-filter treatment used during a heart transplant can improve how the transplant goes for adults. You might be eligible if you’re having a heart transplant and meet the specific medication and procedure requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and scheduled for a heart transplant
- You agree to and sign informed consent (you cannot decline)
- You are not taking anti-leukocyte medicines
- You are not receiving TNF-alpha blockers or certain immune-suppressing medicines (for example, tocilizumab)
- You are not using donor heart donation after circulatory death (DCD)
- This is not an ex-vivo (outside the body) heart perfusion procedure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
This study looks at how well donor hearts work and how that affects outcomes after heart transplantation. It may help transplant teams choose and use donor hearts more effectively.
This Swedish study tests whether a simple blood test can detect early signs that your body is rejecting a transplanted heart. The test looks for DNA fragments in your blood that may signal rejection before symptoms appear, potentially helping doctors catch problems sooner.
This trial tests a new cooling method to safely transport donor hearts. It is for people receiving only a heart transplant (no other organs at the same time).
This early-phase study tests a cell treatment (Treg cells made from a child’s thymus tissue) to help prevent the body from rejecting a new heart. It may help reduce rejection risk, but it is experimental and involves added risks and follow-up.
This trial looks at how a blood-filtering treatment called hemoadsorption affects patients' health and lab results. It may help people who are already receiving this therapy.
Hear when a new Heart Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.